[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR005987A1 - Terapia combinada para la osteoporosis - Google Patents

Terapia combinada para la osteoporosis

Info

Publication number
AR005987A1
AR005987A1 ARP970100746A ARP970100746A AR005987A1 AR 005987 A1 AR005987 A1 AR 005987A1 AR P970100746 A ARP970100746 A AR P970100746A AR P970100746 A ARP970100746 A AR P970100746A AR 005987 A1 AR005987 A1 AR 005987A1
Authority
AR
Argentina
Prior art keywords
osteoporosis
combined therapy
antagonists
compositions
agonists
Prior art date
Application number
ARP970100746A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR005987A1 publication Critical patent/AR005987A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Composiciones de combinaciones farmacéuticas que incluyen determinados agonistas/antagonistas de estrógenos y agonistas/antagonista deprostaglandinas. Las composiciones son útiles para el tratamiento de trastornos óseos incluyendo laosteoporosi s.
ARP970100746A 1996-02-28 1997-02-24 Terapia combinada para la osteoporosis AR005987A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1241296P 1996-02-28 1996-02-28

Publications (1)

Publication Number Publication Date
AR005987A1 true AR005987A1 (es) 1999-07-21

Family

ID=21754846

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970100746A AR005987A1 (es) 1996-02-28 1997-02-24 Terapia combinada para la osteoporosis
ARP070101915A AR060853A2 (es) 1996-02-28 2007-05-03 Composicion farmaceutica para la osteoporosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070101915A AR060853A2 (es) 1996-02-28 2007-05-03 Composicion farmaceutica para la osteoporosis

Country Status (45)

Country Link
US (2) US6323232B1 (es)
EP (3) EP1932543A3 (es)
JP (2) JPH11504352A (es)
KR (1) KR19990087337A (es)
CN (5) CN1515258A (es)
AP (3) AP975A (es)
AR (2) AR005987A1 (es)
AT (1) ATE405273T1 (es)
AU (1) AU703285B2 (es)
BG (1) BG64582B1 (es)
BR (1) BR9612533A (es)
CA (1) CA2247420C (es)
CL (1) CL2004000119A1 (es)
CO (1) CO4761063A1 (es)
CZ (1) CZ297452B6 (es)
DE (1) DE69637651D1 (es)
DK (1) DK0883404T3 (es)
DZ (1) DZ2186A1 (es)
ES (1) ES2312169T3 (es)
GT (2) GT199700009A (es)
HK (1) HK1018210A1 (es)
HN (1) HN1996000101A (es)
HR (1) HRP970118A2 (es)
HU (1) HUP9904123A3 (es)
ID (1) ID19886A (es)
IL (3) IL125493A0 (es)
IS (1) IS4812A (es)
MA (1) MA26420A1 (es)
NO (2) NO323648B1 (es)
NZ (1) NZ323456A (es)
OA (1) OA10837A (es)
PE (2) PE20011302A1 (es)
PL (2) PL187219B1 (es)
PT (1) PT883404E (es)
RU (1) RU2190395C2 (es)
SI (1) SI0883404T1 (es)
SK (1) SK118398A3 (es)
TN (1) TNSN97040A1 (es)
TR (1) TR199801679T2 (es)
TW (1) TW464496B (es)
UA (1) UA69372C2 (es)
UY (1) UY24472A1 (es)
WO (1) WO1997031640A1 (es)
YU (1) YU7797A (es)
ZA (1) ZA971719B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
AU7349298A (en) 1997-06-23 1999-01-04 Pfizer Inc. Prostaglandin agonists
ID24759A (id) * 1997-09-09 2000-08-03 Procter & Gamble Metoda untuk meningkatkan volume tulang
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP0950417A3 (en) * 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
OA11557A (en) * 1998-06-03 2004-05-24 Pfizer Prod Inc 2-Aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors.
PT966968E (pt) 1998-06-16 2004-08-31 Pfizer Prod Inc Combinacoes terapeuticas compreendendo um modulador de receptor de estrogenio selectivo e prostaglandina e2
CA2335112A1 (en) * 1998-06-16 1999-12-23 Hua Zhu Ke Therapeutic combinations for musculoskeletal frailty
AP9901582A0 (en) * 1998-06-16 1999-06-30 Pfizer Prod Inc Combination therapy for musculoskeletal frailty.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
HUP0104192A3 (en) 1998-11-03 2003-12-29 Pfizer Prod Inc Novel macrolide antibiotics
NZ513827A (en) * 1999-03-05 2001-09-28 Procter & Gamble Methods of increasing bone volume using non-naturally-occurring FP selective agonists and antiresorptive compounds
GB9913649D0 (en) * 1999-06-11 1999-08-11 Karobio Ab Estrogen receptor
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
WO2001091724A2 (en) * 2000-06-01 2001-12-06 Watson Pharmaceuticals, Inc. Transdermal delivery of lasofoxifene
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
ES2233570T3 (es) * 2000-11-30 2005-06-16 Pfizer Products Inc. Composicion que contiene agonistas/antagosnistas de estrogenos y testosterona para tratar un descenso en el nivel de la hormona testosterona.
EP1411922A1 (en) * 2001-07-31 2004-04-28 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
UY28089A1 (es) * 2002-11-26 2004-06-30 Smithkline Beecham Corp Compuestos calciliticos
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2849910A1 (en) 2011-09-30 2013-04-04 Perio Sciences, Llc Antioxidant compositions for treatment of inflammation or oxidative damage
CN103142644B (zh) * 2013-03-21 2014-07-23 青岛正大海尔制药有限公司 骨化三醇和氟化钠的混悬颗粒及其制备方法
MX2019004184A (es) 2016-10-11 2019-09-27 Univ Duke Tratamiento con lasofoxifeno del cancer de mama.
CN112261937B (zh) 2018-04-10 2023-11-14 杜克大学 乳腺癌的拉索昔芬治疗
CN112384634B (zh) * 2018-04-24 2024-04-16 深圳华大生命科学研究院 骨质疏松生物标志物及其用途
CN110412289B (zh) * 2019-07-25 2022-08-02 北京美迪阿姆科技发展有限公司 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
BE637389A (es) 1962-09-13
US3522319A (en) 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3927197A (en) 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US3982016A (en) 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4000309A (en) 1975-08-06 1976-12-28 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4132847A (en) 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4097601A (en) 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4219483A (en) 1978-09-11 1980-08-26 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4621100A (en) 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4904478A (en) 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
DE3583887D1 (de) 1984-04-30 1991-10-02 Procter & Gamble Ausruestung fuer die behandlung der osteoporose.
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3762617D1 (de) 1986-09-11 1990-06-13 Nat Res Dev Tamoxifenderivate.
US5216183A (en) 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
AU645874B2 (en) 1990-11-26 1994-01-27 Robert R. Recker Treatment for osteoporosis using growth hormone release factor (GRF) in combination with parathyroid hormone (PTH)
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
US5180720A (en) 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
CZ151495A3 (en) 1992-12-11 1995-12-13 Merck & Co Inc Spiropiperidine derivatives, process of their preparation and a pharmaceutical composition containing thereof
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW303299B (es) * 1993-07-22 1997-04-21 Lilly Co Eli
HUT75224A (en) * 1993-10-19 1997-04-28 Merck & Co Inc Combination of bisphosphonates and growth hormone secretagogues
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
KR960705808A (ko) 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
CA2176140A1 (en) 1993-11-24 1995-06-01 Meng Hsin Chen Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5441966A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
US5777112A (en) 1994-06-13 1998-07-07 Merck & Co., Inc Piperazine compounds promote release of growth hormone
EP0779813A4 (en) * 1994-09-09 1998-05-06 Procter & Gamble PHOSPHONATES AND PARATHORMONE AGAINST OSTEOPOROSIS
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6100301A (en) 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
IL120270A0 (en) 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
HU229057B1 (en) 1996-05-07 2013-07-29 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
EP0907374A1 (en) 1996-05-31 1999-04-14 Novo Nordisk A/S Growth hormone component and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
BR9803596A (pt) 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea

Also Published As

Publication number Publication date
PE20011302A1 (es) 2001-12-25
RU2190395C2 (ru) 2002-10-10
DZ2186A1 (fr) 2002-12-02
CN1515317A (zh) 2004-07-28
CO4761063A1 (es) 1999-04-27
DE69637651D1 (en) 2008-10-02
AP2000001962A0 (en) 2000-12-31
YU7797A (sh) 2000-10-30
HRP970118A2 (en) 1998-04-30
PL187962B1 (pl) 2004-11-30
TNSN97040A1 (fr) 2005-03-15
CN1515316A (zh) 2004-07-28
OA10837A (en) 2001-08-13
CN1515258A (zh) 2004-07-28
CN1515254A (zh) 2004-07-28
AU1039897A (en) 1997-09-16
UY24472A1 (es) 2000-09-29
EP1236475A2 (en) 2002-09-04
EP0883404B1 (en) 2008-08-20
DK0883404T3 (da) 2008-10-20
HN1996000101A (es) 1997-06-26
JP2002308771A (ja) 2002-10-23
US20010009920A1 (en) 2001-07-26
TR199801679T2 (xx) 2001-06-21
PL328831A1 (en) 1999-02-15
CZ297452B6 (cs) 2006-12-13
AR060853A2 (es) 2008-07-16
NO323648B1 (no) 2007-06-18
NZ323456A (en) 2001-03-30
CZ271898A3 (cs) 1999-06-16
EP0883404A1 (en) 1998-12-16
AP2002002661A0 (en) 2002-12-31
BG64582B1 (bg) 2005-08-31
GT199700009A (es) 1998-07-10
HUP9904123A3 (en) 2001-01-29
CA2247420A1 (en) 1997-09-04
PL187219B1 (pl) 2004-06-30
SI0883404T1 (sl) 2008-10-31
TW464496B (en) 2001-11-21
EP1236475A3 (en) 2003-11-05
GT199700009AA (es) 1999-01-23
AP1179A (en) 2003-06-30
KR19990087337A (ko) 1999-12-27
PE58998A1 (es) 1998-10-16
ATE405273T1 (de) 2008-09-15
WO1997031640A1 (en) 1997-09-04
JPH11504352A (ja) 1999-04-20
MA26420A1 (fr) 2004-12-20
BR9612533A (pt) 1999-07-20
BG102726A (en) 1999-04-30
IL154379A0 (en) 2003-09-17
ES2312169T3 (es) 2009-02-16
US6323232B1 (en) 2001-11-27
HK1018210A1 (en) 1999-12-17
NO20063853L (no) 1998-08-27
ID19886A (id) 1998-08-13
AU703285B2 (en) 1999-03-25
AP9700934A0 (en) 1997-04-30
ZA971719B (en) 1998-08-27
UA69372C2 (en) 2004-09-15
EP1932543A3 (en) 2012-01-04
NO983936D0 (no) 1998-08-27
IL154380A0 (en) 2003-09-17
PT883404E (pt) 2008-11-14
CN1209064A (zh) 1999-02-24
SK118398A3 (en) 2000-07-11
US7255984B2 (en) 2007-08-14
IS4812A (is) 1998-07-28
HUP9904123A2 (hu) 2000-05-28
EP1932543A2 (en) 2008-06-18
NO983936L (no) 1998-08-27
AP974A (en) 2001-06-12
CN1242813C (zh) 2006-02-22
CL2004000119A1 (es) 2005-02-11
IL125493A0 (en) 1999-03-12
AP975A (en) 2001-06-12
CA2247420C (en) 2011-02-15

Similar Documents

Publication Publication Date Title
AR005987A1 (es) Terapia combinada para la osteoporosis
GT199800158AA (es) Agonistas de prostaglandinas y su uso para tratar trastornos oseos
PA8452701A1 (es) Agonistas de prostaglandinas
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
ES2191320T3 (es) Derivados de piperazina y su uso como agentes anti-inflamatorios.
ES2088006T3 (es) Composiciones farmaceuticas osteoinductivas.
CR20120007A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
EP0911321A3 (en) Compounds for the treatment of osteoporosis
AR016981A2 (es) Polipeptidos sinteticos
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
EA200001199A1 (ru) Терапевтические комбинации, содержащие селективный модулятор рецептора эстрогена и паратироидный гормон
ECSP003590A (es) Compuestos calcioliticos
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
UY26651A1 (es) Terapia combinada para la osteoporosis
ES2082559T3 (es) Nuevas composiciones de agentes frigorificos.
ECSP982698A (es) Agonistas de prostaglandinas
ECSP982554A (es) Agonistas de prostaglandinas

Legal Events

Date Code Title Description
FC Refusal